ArticleAmerican journal of physiology. Renal physiology2012
Role of blood pressure and the renin-angiotensin system in development of diabetic nephropathy (DN) in eNOS-/- db/db mice.
Article in American journal of physiology. Renal physiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 45 citations in OpenAlex.
- Reconstituted HDL ameliorated renal injury of diabetic kidney disease in mice.Physiological reports · 2024Article
- Potential Medicinal Value of Rhein for Diabetic Kidney Disease.Chinese journal of integrative medicine · 2023Review
- Sex and strain differences in renal hemodynamics in mice.Physiological reports · 2023Article
- Captopril alleviates lung inflammation in SARS-CoV-2-infected hypertensive mice.Zoological research · 2021Article
- Renin-angiotensin system inhibition reverses the altered triacylglycerol metabolic network in diabetic kidney disease.Metabolomics : Official journal of the Metabolomic Society · 2021Article
- Regulation of Monocytes/Macrophages by the Renin-Angiotensin System in Diabetic Nephropathy: State of the Art and Results of a Pilot Study.International journal of molecular sciences · 2021Review
- Gene expression profiles of diabetic kidney disease and neuropathy in eNOS knockout mice: Predictors of pathology and RAS blockade effects.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021Article
- Podocyte EGFR Inhibits Autophagy Through Upregulation of Rubicon in Type 2 Diabetic Nephropathy.Diabetes · 2021Article
- Comparison of diabetic nephropathy between male and female eNOSAmerican journal of physiology. Renal physiology · 2019Article
- Ramipril can alleviate the accumulation of renal mesangial matrix in rats with diabetic nephropathy by inhibiting insulin-like growth factor-1.Acta cirurgica brasileira · 2019Article
- Assessment of renal fibrosis in murine diabetic nephropathy using quantitative magnetization transfer MRI.Magnetic resonance in medicine · 2018Article
- Article
- CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease.Nature reviews. Nephrology · 2018Review
- Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control.JCI insight · 2018Article
- Progressive Renal Disease Established by Renin-Coding Adeno-Associated Virus-Driven Hypertension in Diverse Diabetic Models.Journal of the American Society of Nephrology : JASN · 2018Article
- Modelling diabetic nephropathy in mice.Nature reviews. Nephrology · 2018Review
- Lysophosphatidic Acid Receptor Antagonism Protects against Diabetic Nephropathy in a Type 2 Diabetic Model.Journal of the American Society of Nephrology : JASN · 2017Article
- Article
- Lysyl Oxidase-like-2 Cross-links Collagen IV of Glomerular Basement Membrane.The Journal of biological chemistry · 2016Article
- Mapping murine diabetic kidney disease using chemical exchange saturation transfer MRI.Magnetic resonance in medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Randomized clinical trials have clearly shown that inhibition of the renin-angiotensin system (RAS) will slow the rate of progression of diabetic nephropathy, but controversy remains about whether the observed beneficial effects result from more than control of blood pressure. Deletion of eNOS in a model of type II diabetes, db/db mice (eNOS(-/-) db/db), induces an accelerated nephropathy and provides an excellent model of human diabetic nephropathy. As is frequently seen in type II diabetes, blood pressure is moderately elevated in eNOS(-/-) db/db mice. To determine the role of elevated blood pressure per se vs. additional deleterious effects of the RAS in mediation of disease progression, 8-wk-old eNOS(-/-) db/db mice were randomly divided into three groups: vehicle, treatment with the angiotensin-converting enzyme inhibitor (ACEI) captopril, or treatment with "triple therapy" (hydralazine, resperine, hydrocholorothiazide), and the animals were euthanized after treatment for 12 wk. Blood pressure was reduced to comparable levels with ACE inhibition or triple therapy. Although both treatment regimens decreased development of diabetic nephropathy, ACE inhibition led to more profound reductions in albuminuria, glomerulosclerosis, markers of tubulointerstitial injury, macrophage infiltration, and markers of inflammation. Therefore, this animal model suggests that while there is an important role for blood pressure control, RAS blockade provides additional benefits in slowing the progression of diabetic nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.